Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Non-Hodgkin's lymphoma patients with prior therapy who satisfy the conditions listed below. No restrictions regarding gender.~* Patients with histologically or cytologically confirmed indolent B cell Non-Hodgkin's lymphoma or mantle cell lymphoma.~* Patients who had not received treatment for at least 4 weeks (for at least 12 weeks in the case of antibody therapy) after completion of prior therapy and who are judged to carry no effect from the prior therapy.~* Patients aged from 20 to less than 75 years.~* Performance Status (P.S.): 0 or 1.~* Patients with adequately maintained organ functions (e.g., bone marrow, heart, lung, liver, and kidney functions).~* Patients from whom written consent to participate in this study has been obtained.~Exclusion Criteria:~Patients who meet any of the following criteria will be excluded.~* Patients with apparent infections.~* Patients with serious complications (hepatic failure or renal failure).~* Patients with complication or history of serious heart failure (e.g. cardiac infarction, ischemic heart disease).~* Patients with serious digestive symptoms (nausea/ vomiting/ diarrhea).~* Patients who are known to be positive for HBV, HCV or HIC.~* Patients receiving other investigational drugs within 3 months before registration in the study.~* Patients with allogenic bone-marrow transplant.~* Women who are pregnant, of childbearing potential, or lactating.~* Patients who do not agree to contraception.~* Otherwise, patients who are judged by the investigator as being unsuitable for inclusion in the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).